Xellia Pharmaceuticals is a global leader in providing critical care therapies and anti-infective treatments for serious and life-threatening infections. With over 120 years of pharmaceutical industry experience, Xellia manufactures and supplies Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) to over 500 pharmaceutical companies across 80 countries.
Headquartered in Copenhagen, Denmark, Xellia Pharmaceuticals is owned by Novo Holdings A/S and has a strong market position with state-of-the-art manufacturing sites in the U.S., China, Denmark, and Hungary. Committed to enhancing patient care, Xellia focuses on innovation, convenience, and ease of use for healthcare professionals, building a pipeline of value-added critical care therapies.
Generated from the website